A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.

There was a progressive decrease in the baseline IPSS at different follow-up visits with alfuzosin, the maximum decline (62.14%) occurring at 2 weeks and the overall decrease at the end of the study period being 88.18%, which was highly significant ( P < 0.001).

also in 132,142 other papers